Translation of "Fibrates" in German

Adequate pharmacovigilance and pharmacokinetic data are not available for other fibrates.

The use of fibrates alone is occasionally associated with myopathy.

The combined use of a statin and fibrates should generally be avoided.

Fibrates (such as bezafibrate, fenofibrate, gemfibrozil used to lower the level of fats)

In many ways, the pharmacological activity of pterostilbene resembles the action of fibrates.

It belongs to a group of drugs known as fibrates.

Lopid belongs to the class of medications known as fibrates.

As for others HMG-CoA reductase inhibitors, combination of pravastatin with fibrates is not recommended.

This reciprocal increase in LDL cholesterol usually means that fibrates alone do not lower non-HDL cholesterol level.

Among these substances, the fibrates (benzafibrate, clofibrate, etofibrate and fenofibrate) are preferred.

Almost all subjects (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).

These included: nonsteroidal anti-inflammatory agents (including acetylsalicylic acid), anilides (such as paracetamol), H2 blockers and proton pump inhibitors, diuretics, digoxin and cardiac glycosides, organic nitrates and other vasodilators for cardiac diseases, calcium channel blockers, beta blockers, ACE inhibitors, angiotensin II antagonists, selective beta-2 adrenoceptor agonists, oral anticoagulants, platelet aggregation inhibitors, statins, fibrates and benzodiazepine derivatives.

The risk of myopathy and rhabdomyolysis is also increased by concomitant use of other fibrates, lipid-lowering doses (? 1 g/ day) of niacin or by concomitant use of amiodarone or verapamil with higher doses of simvastatin (see sections 4.2 and 4.5).

In pivotal phase III clinical trials the following medicinal products were routinely combined with ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other antiplatelet medicinal products.

Based on the above, the CHMP recommended the amendments of the marketing authorisations and concluded that the benefit risk profile of fibrates is still positive in the agreed indications.

However, the effect of fibrates mainly on triglycerides but also a smaller but overall positive effect on HDL and LDL cholesterol suggest that there are subgroups of patients who may still benefit from this therapy.

Fibrates have been shown to reduce plasma triglycerides (TG) by 30% to 50% and raise the level of high density lipoprotein cholesterol (HDL-C) by 2% to 20%.

The fibrates share a common mechanism of action and exert qualitatively similar effects on serum lipid triglycerides (decrease) and HDL-cholesterol concentrations (increase).

However in severe hypertriglyceridaemia and certain dyslipidaemias where a statin cannot be used patients can still benefit from treatment with fibrates.

Fibrates (fenofibrate, bezafibrate, ciprofibrate and gemfibrozil) are a class of lipid-lowering drugs and exert their effects mainly by activating the peroxisome proliferator-activated receptor-alpha (PPARalpha), apart from bezafibrate which is an agonist for all three PPAR isoforms alpha, gamma, and delta.

Overall the available evidence suggested that despite the long presence of fibrates on the market, there is only limited evidence of a long term clinical benefit from their use in the primary or secondary prevention of cardiovascular disease.